Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Brain Neoplasms 10Glioblastoma 6Glioma 4Astrocytoma 3Oligodendroglioma 2Neoplasm Metastasis 2Central Nervous System Neoplasms 2Supratentorial Brain Tumor 1Neoplasms 1Melanoma 1Central Nervous System Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Temozolomide 3gadobenic acid 2XENP 1595 2Trastuzumab 2Sodium Chloride 2Dexmedetomidine 2Cancer Vaccines 2Adjuvants, Immunologic 2veliparib 1tucatinib 1tipifarnib 1sagopilone 1pembrolizumab 1interferon gamma-1b 1glutathione pegylated liposomal doxorubicin 1gadoteridol 1elacestrant 1abemaciclib 1Tissue Banks 1Saline Solution 1Rituximab 1Radiotherapy 1Radiation 1RAD1901 1Oncolytic Virotherapy 1Interferon-gamma 1Immunotherapy 1Dasatinib 1Craniotomy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Diseases × Craniotomy × Clear all
NCT00805376 2018-07-16

DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas

DNAtrix, Inc.

Phase 1 Completed
37 enrolled
CNS

Brain Neoplasms, Central Nervous System Diseases, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡